Citation Context
...will approach that of the plasma volume if the rate of release ofsthe drug is low. Even with a rapid drug release, the improvement in solubility of the drug andsreduction in drug toxicity may be seen =-=[123]-=-. Surface modifications of the DDS, such assPEGylation, may dramatically change the circulation time, as discussed in the next section.sSurface characteristics contribute to the DDS solubility, aggreg...
\"... permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. A liposome formulation for paclitaxel was developed in this study. The liposomes, composed of naturally unsaturated and hydrogenated phosphatidylcholines, with significant phase tran ...\" Abstract - Add to MetaCart permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. A liposome formulation for paclitaxel was developed in this study. The liposomes, composed of naturally unsaturated and hydrogenated phosphatidylcholines, with significant phase transition temperature difference, were prepared and characterized. The liposomes exhibited a high content of paclitaxel, which was incorporated within the segregated microdomains coexisting on phospholipid bilayer of liposomes. As much as 15 % paclitaxel to phospholipid molar ratio were attained without precipitates observed during preparation. In addition, the liposomes remained stable in liquid form at 4 ◦ C for at least 6 months. The special composition of liposomal membrane which could reduce paclitaxel aggregation could account for such a capacity and stability. The cytotoxicity of prepared paclitaxel liposomes on the colon cancer C-26 cell culture was comparable to Taxol. Acute toxicity test revealed that LD50 for intravenous bolus injection in mice exceeded by 40 mg/kg. In antitumor efficacy study, the prepared liposomal paclitaxel demonstrated the increase in the efficacy against human cancer in animal model. Taken together, the novel formulated liposomes can incorporate high content of paclitaxel, remaining stable for long-term storage. These animal data also demonstrate that the liposomal paclitaxel is promising for further clinical use. 1.Citation Context
...eek of storage at 4 ◦ C. On the other hand, the liposomal formulations of paclitaxel consisting of a special negatively charged phospholipid, cardiolipid, and phosphatidyl choline have been described =-=[21]-=-. Increasing the paclitaxel/lipid molar ratio to 9% causes the liposomes to be stable for only one month when stored in liquid form at 4 ◦ C[21]. For the 3% drug-to-lipid ratio of liposomal paclitaxel...
\"... ABSTRACT: Atherosclerosis, an inflammatory lipid-rich plaque disease is perpetuated by the unregulated scavenger-receptor-mediated uptake of oxidized lipoproteins (oxLDL) in macrophages. Current treatments lack the ability to directly inhibit oxLDL accumulation and foam cell conversion within diseas ...\" Abstract - Add to MetaCart ABSTRACT: Atherosclerosis, an inflammatory lipid-rich plaque disease is perpetuated by the unregulated scavenger-receptor-mediated uptake of oxidized lipoproteins (oxLDL) in macrophages. Current treatments lack the ability to directly inhibit oxLDL accumulation and foam cell conversion within diseased arteries. In this work, we harness nanotechnology to design and fabricate a new class of nanoparticles (NPs) based on hydrophobic mucic acid cores and amphiphilic shells with the ability to inhibit the uncontrolled uptake of modified lipids in human macrophages. Our results indicate that tailored NP core and shell formulations repress oxLDL internalization via dual complementary mechanisms. Specifically, the most atheroprotective molecules in the NP cores competitively reduced NP-mediated uptake to scavenger receptor A (SRA) and also down-regulated the surface expression of SRA and CD36. Thus, nanoparticles can be designed to switch activated, lipid-scavenging macrophages to antiatherogenic phenotypes, which could be the basis for future antiatherosclerotic therapeutics. Paul Brian Latimer, Kimberly Kline Co-supervisor, Bob G. S, Nomeli Nunez, Jeanne Freeland-graves, Claudio Conti, Paul Brian LatimerCitation Context
...e has been shown to causeshypersensitivity reactions in humans.sIn response to the need for a more effectivesdelivery method, liposomes were found to be a viable alternative for clinical use of Taxols=-=(121,122)-=-s103sIn the following study we compared the effectiveness of using aerosol Taxol deliveredsevery other day for two weeks, followed by daily aerosol α-TEA treatments, inscomparison to untreated and lip...
